Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.

• To assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of the -secretase inhibitor avagacestat in patients with mild to moderate Alzheimer disease (AD).

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Nyckelord

Activities of Daily Living

Aged

Aged

80 and over

Alzheimer Disease

diagnosis

drug therapy

metabolism

psychology

Amyloid Precursor Protein Secretases

antagonists & inhibitors

Amyloid beta-Peptides

cerebrospinal fluid

Body Weight

drug effects

Dose-Response Relationship

Drug

Double-Blind Method

Enzyme Inhibitors

blood

therapeutic use

Female

Humans

Immunoprecipitation

International Cooperation

Magnetic Resonance Imaging

Male

Mass Spectrometry

Middle Aged

Neuropsychological Tests

Outcome Assessment (Health Care)

Oxadiazoles

blood

therapeutic use

Psychiatric Status Rating Scales

Sulfonamides

blood

therapeutic use

Time Factors

tau Proteins

cerebrospinal fluid

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)